The impact of very high initial PSA on oncological outcomes after radical prostatectomy for clinically localized prostate cancer
- 1 May 2020
- journal article
- research article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 38 (5) , 379-385
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® GuidelineJournal of Urology, 2017
- Impact of preoperative risk on metastatic progression and cancer‐specific mortality in patients with adverse pathology at radical prostatectomyBJU International, 2017
- Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7European Urology, 2016
- The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/mlJournal of Urology, 2015
- Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without ComorbidityEuropean Urology, 2013
- High-Risk Prostate Cancer: From Definition to Contemporary ManagementEuropean Urology, 2012
- Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trialThe Lancet, 2011
- Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trialThe Lancet, 2009
- Biochemical disease‐free survival in patients with a high prostate‐specific antigen level (20–100 ng/mL) and clinically localized prostate cancer after radical prostatectomyBJU International, 2003
- Cancer-Specific Mortality After Surgery or Radiation for Patients With Clinically Localized Prostate Cancer Managed During the Prostate-Specific Antigen EraJournal of Clinical Oncology, 2003